Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cells

International Journal of Cancer

Volumn 116, Issue 1, 2005, Pages 78-86

  Stärck, Lilian ^a   Scholz, Christian ^a   Blankenstein, Thomas ^b   Dörken, Bernd ^a   Daniel, Peter T ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Apoptosis; CD80; Costimulation; Irradiation; Necrosis

Indexed keywords

B7 ANTIGEN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IRRADIATION; NECROSIS; PRIORITY JOURNAL; RHABDOMYOSARCOMA; T CELL DEPLETION; T LYMPHOCYTE; TRANSGENE; TUMOR CELL;

ANTIGENS, CD80; CANCER VACCINES; CELL DEATH; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; RHABDOMYOSARCOMA; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 20444443560     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20792     Document Type: Article

References (48)

1. Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109:295-9.
2. Blankenstein T, Cayeux S, Qin Z. Genetic approaches to cancer immunotherapy. Rev Physiol Biochem Pharmacol 1996;129:1-49.
3. Cayeux S, Beck C, Aicher A, Dörken B, Blankenstein T. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995;25:2325-31.
4. Cayeux S, Beck C, Dörken B, Blankenstein T. Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 1996;7:525-9.
5. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-76.
6. Willimsky G, Blankenstein T. Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors. Cancer Res 2000;60:685-92.
7. Scholz C, Stärck L, Willimsky G, Blankenstein T, Dörken B, Daniel PT. Adenoviral transduction of tumor cells induces apoptosis in cocultured T lymphocytes. Gene Ther 2002;9:1438-46.
8. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B, Pezzutto A. Immunotherapy of B-cell lymphoma with CD3×19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 1998; 92:4750-7.
9. Vermerken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG Jr, Pinedo HM. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353:345-50.
10. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
11. Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, Williamson S, Jewell W, Suzuki T. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 2001;50:373-81.
12. Nawrocki S, Murawa P, Malicki J, Kapcinska M, Gryska K, Izycki D, Kaczmarek A, Laciak M, Czapczyk A, Karczewska A, Rose-John S, Mackiewicz A. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 2000;74:81-6.
13. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17: 1047-60.
14. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmitt E, Dannenberg T, Lehmacher W, von Wietersheim J, Doehn C. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363:594-9.
15. Shinomiya N. New concepts in radiation-induced apoptosis: "premitotic apoptosis" and "postmitotic apoptosis." J Cell Mol Med 2001;5:240-53.
16. Harms-Ringdahl M, Nicotera P, Radford IR. Radiation induced apoptosis. Mutat Res 1996;366:171-9.
17. Zhou L, Yuan R, Serggio L. Molecular mechanisms of irradiation-induced apoptosis. Front Biosci 2003;8:D9-19.
18. Hock H, Dorsch M, Kunzendorf U, Uberla K, Qin Z, Diamantstein T, Blankenstein T. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 1993;53:714-6.
19. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
20. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995;184:39-51.
21. Vermes I, Haanen C, Richel DJ, Schaafsma MR, Kalsbeek-Batenburg E, Reutelingsperger CP. Apoptosis and secondary necrosis of lymphocytes in culture. Acta Haematol 1997;98:8-13.
22. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dörken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997;159:3808-15.
23. Daniel PT, Oettinger U, Mapara MY, Bommert K, Bargou R, Dörken B. Activation and activation-induced death of human tonsillar B cells and Burkitt lymphoma cells: lack of CD95 (Fas/APO-1) ligand expression and function. Eur J Immunol 1997;27:1029-34.
24. Gillissen B, Essmann F, Graupner V, Stärck L, Radetzki S, Dörken B, Schulze-Osthoff K, Daniel PT. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 2003;22:3580-90.
25. Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, Dörken B, Daniel PT. Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-xL in a strictly caspase-3-dependent manner in human carcinoma cells. Oncogene 2004; 23:4523-35.
26. Friedrich K, Wieder T, Von Haefen C, Radetzki S, Janicke R, Schulze-Osthoff K, Dörken B, Daniel PT. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 2001;20:2749-60.
27. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dörken B, Schmalz HG, Daniel PT, Henze G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 2001;15:1735-42.
28. Kotera Y, Shimizu K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 2001;61:8105-9.
29. Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101: 1718-26.
30. Takahashi S, Yomda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A, Brenner MK. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001;8:378-87.
31. Bowman LC, Grossmann M, Rill D, Brown M, Zhong WY, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Brenner M. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998;9:1303-11.
32. Yannelli JR, Hyatt C, Johnson S, Hwu P, Rosenberg SA. Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2). J Immunol Methods 1993;161:77-90.
33. Graf MR, Prins RM, Hawkins WT, Merchant RE. Irradiated tumor cell vaccine for treatment of an established glioma: I, successful treatment with combined radiotherapy and cellular vaccination. Cancer Immunol Immunother 2002;51:179-89.
34. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993;90:2774-8.
35. Daniel PT, Scholz C, Essmann F, Westermann J, Pezzutto A, Dörken B. CD95/Fas-triggered apoptosis of activated T lymphocytes is prevented by dendritic cells through a CD58-dependent mechanism. Exp Hematol 1999;27:1402-8.
36. Cayeux S, Richter G, Noffz G, Dörken B, Blankenstein T. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997;158:2834-41.
37. Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nobetaner E, Willimsky G, Maget B, Pohla H, Blankenstein T. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 2000;7:2007-14.
38. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992;149:3166-73.
39. Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994; 152:5624-32.
40. Gärtner HV, Seidl C, Luckenbach C, Schumm G, Seifried E, Ritter H, Bultmann B. Genetic analysis of a sarcoma accidentally transplanted from a patient to a surgeon. N Engl J Med 1996;335:1494-6.
41. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001;15:1022-32.
42. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP, Greten TF. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003;103:205-11.
43. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Robe J, Endres S, Eigler A. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res 2002;62:2347-52.
44. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4:581-7.
45. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000;12:1539-46.
46. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55.
47. Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 2000;60:6441-7.
48. Davis MM, Krogsgaard M, Huppa JB, Sumen C, Purbhoo MA, Irvine DJ, Wu LC, Ehrlich L. Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem 2003;72:717-42.